Unveiling diagnostic biomarkers and therapeutic targets in lung adenocarcinoma using bioinformatics and experimental validation

利用生物信息学和实验验证揭示肺腺癌的诊断生物标志物和治疗靶点

阅读:1

Abstract

Lung adenocarcinoma (LUAD) is a major challenge in oncology due to its complex molecular structure and generally poor prognosis. The aim of this study was to find diagnostic markers and therapeutic targets for LUAD by integrating differential gene expression analysis, weighted gene co-expression network analysis (WGCNA), and machine learning methods. Differentially expressed genes (DEGs) were identified through the analysis of gene expression data from the Gene Expression Omnibus (GEO) database. Ten of the gene co-expression modules constructed by WGCNA were identified, with the red module having the most significant correlation with clinical features. In addition, a machine learning model constructed based on Stepglm[backward] with the random forest algorithm achieved the highest C-index (0.999) and screened eight core genes, among which ST14 was noted for its excellent predictive ability. Single-cell RNA sequencing of the LUAD samples further analyzed the expression patterns of these genes in 29 cellular subtypes, revealing their significant association with immune cell infiltration. Of particular note, the association of ST14 with clinical prognosis, drug responsiveness, and immune infiltration was validated, while enrichment analysis further clarified its role in key biological pathways. Ultimately, the expression of the core genes was validated experimentally. This study provides new insights into the pathogenesis of LUAD, clarifies potential diagnostic markers and therapeutic targets, and provides an important basis for future clinical interventions.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。